NEW YORK, Aug. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS). Shareholders who purchased shares of MRNS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/marinus-pharmaceuticals-inc-loss-submission-form/? id=93530&from=4 CLASS ...

NEW YORK, Aug. 3, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024, both dates inclusive (the "Class Period"), of the important August 5, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Marinus securities during the Class Period you may be entitled to compensation without payment of any out of pocket ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Marinus stock or options between March 17, 2021 and May 7, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247- 4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/MRN ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Marinus investors who were adversely affected by alleged securities fraud between March 17, 2021 and May 7, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/marinus-pharmaceuti ...

CLASS PERIOD: March 17, 2021 to May 7, 2024 Shareholders who purchased shares of MRNS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/marinus-pharmaceuticals-inc-loss-submission-form/? id=92718&from=3 NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Mar ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024, both dates inclusive (the "Class Period"), of the important August 5, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. WHAT TO DO NEXT: To join the Marinus class action, go to https://rosenlegal.com/submit-form/? case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenl ...

Then, on May 8, 2024, before the market opened, the Company filed with the SEC a current report on Form 8- K. Attached to this Form 8-K was a press release in which the Company announced that it would stop clinical trial enrollment in the RAISE and RAISE II trials. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequa ...

The Rosen Law Firm is investigating the Allegations that Marinus Pharmaceuticals, Inc. (MRNS) Misled Investors Regarding its Business Operations. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. To join the Marinus class action, go to https://rosenlegal.com/submit-form/?case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected]. Plaintiff alleges that on May 8, 2024, Fierce Biotech published an article which illustrated the impact on t ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) and reminds investors of the August 5, 2024 deadline to seek the role of lead plaintiff in a federal ...

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants' statements ...